



VPI/96-16 CIP US

TECH CENTER 1600/2900

FEB 25 2003

RECEIVED

Exhibit 1

Appendix of Claim Amendments

26. (Three Times Amended) A method of treating inflammatory diseases, [autoimmune diseases,] destructive bone disorders, [infectious diseases, neurodegenerative diseases,] reperfusion/ischemia in stroke, myocardial ischemia, renal ischemia, [heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia,] cardiac hypertrophy, [thrombin-induced platelet aggregation or conditions associated with prostaglandin endoperoxide synthase-2] rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, or Crohn's disease in a patient, said method comprising administering to said patient a composition according to claim 25.

28. (Twice Amended) The method according to claim 26, wherein said method is used to treat [an autoimmune disease selected from glomerulonephritis,] rheumatoid arthritis[, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis,] inflammatory bowel disease, ulcerative colitis, or Crohn's disease[, psoriasis, or graft vs. host disease].

34. (Twice Amended) The method according to claim 26, wherein said method is used to treat ischemia/reperfusion in stroke or myocardial ischemia, or renal ischemia[, heart attacks, organ hypoxia or thrombin-induced platelet aggregation].

17

63. (Twice Amended) A method of treating inflammatory diseases, [autoimmune diseases,] destructive bone disorders, [infectious diseases, neurodegenerative diseases,] reperfusion/ischemia in stroke, myocardial ischemia, renal ischemia, [heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia,] cardiac hypertrophy, [thrombin-induced platelet aggregation or conditions associated with prostaglandin endoperoxide synthase-2] rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, or Crohn's disease in a patient, said method comprising administering to said patient a composition according to claim 62.

65. (Twice Amended) A method of treating inflammatory diseases, [autoimmune diseases,] destructive bone disorders, [infectious diseases, neurodegenerative diseases,] reperfusion/ischemia in stroke, myocardial ischemia, renal ischemia, [heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia,] cardiac hypertrophy, [thrombin-induced platelet aggregation or conditions associated with prostaglandin endoperoxide synthase-2] rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, or Crohn's disease in a patient, said method comprising administering to said patient a composition according to claim 64.

67. (Twice Amended) A method of treating inflammatory diseases, [autoimmune diseases,] destructive bone disorders, [infectious diseases, neurodegenerative diseases,] reperfusion/ischemia in stroke, myocardial ischemia, renal ischemia, [heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia,] cardiac hypertrophy, [thrombin-induced platelet aggregation or conditions associated with

F

prostaglandin endoperoxide synthase-2] rheumatoid arthritis,
inflammatory bowel disease, ulcerative colitis, or Crohn's
disease in a patient, said method comprising administering to
said patient a composition according to claim 66.

F